CytoDyn Swaps CEO: CFO Robert Hoffman Takes Over as Lalezari Moves to Research
CYDY sits 37% above its 52-week low of $0.183 on elevated volume (3.8× avg).
Summary
CytoDyn named CFO Robert Hoffman chief executive effective October 20, 2026, with Dr. Jacob Lalezari stepping down from the CEO seat to lead Research and Translational Sciences. Hoffman keeps the principal accounting officer role, concentrating financial control in one person at a company that just reported a $19.9M quarterly loss and reiterated its going concern warning in the October 14 10-Q. The move keeps Lalezari, the public face of leronlimab, on the science side while handing the financing and partnership agenda to the finance chief — a signal that capital-raising and deal-making, not just trials, are now the priority. The company also carries a heavy overhang: a September S-3 and October 424B3 activated resale of roughly 795 million shares by selling stockholders. The November 20 annual meeting, where directors and auditors are up for a vote, is the next scheduled checkpoint.
At the time of this announcement, CYDY was trading at $0.25 on OTC in the Life Sciences sector, with a market capitalization of approximately $367.4M. The 52-week trading range was $0.18 to $0.40. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.